Plain-English translation of NCT03414827 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Kidney Cancer research guide →Researchers are studying the genes of people with kidney cancer to understand what makes some cancers behave differently than others. By collecting and analyzing biological samples from kidney cancer patients, they hope to discover genetic markers—like fingerprints in your cells—that could help doctors predict which patients are at higher risk and which treatments might work best.
Kidney cancer affects many people, but doctors don't yet have reliable ways to predict how aggressive a person's cancer will be or which treatments will be most effective for them. This research aims to fill that gap by identifying genetic clues that could personalize treatment plans and improve outcomes.
You likely qualify if…
You likely don't qualify if…
The study happens in three phases over several months. In the first phase, 10 newly diagnosed patients will be recruited at the hospital to provide samples. Researchers will also use biological samples from 100 additional kidney cancer patients already stored in a national biobank. Finally, 10 patients will be enrolled for final genetic testing. Most participants will need to visit the hospital at least once to provide a blood or tissue sample, which is then analyzed for genetic patterns.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Denmark
Enrollment target
~120 participants
Started
February 2019
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in January 2024.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.